Securities code: Betta Pharmaceuticals Co.Ltd(300558) securities abbreviation: Betta Pharmaceuticals Co.Ltd(300558) Announcement No.: 2022018 Betta Pharmaceuticals Co.Ltd(300558)
Announcement on the resolution of the 23rd Meeting of the third board of supervisors
The company and all members of the board of supervisors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings of the board of supervisors
1. The board of supervisors was convened by Mr. Zhang Yangnan, chairman of the board of supervisors. The meeting notice was sent to all supervisors by e-mail, telephone and other forms on February 25, 2022. The meeting notice of the board of supervisors includes relevant materials of the meeting and lists the time, place, content and method of the meeting.
2. The board of supervisors was held on March 4, 2022 in the conference room on the third floor of the company’s Hangzhou headquarters by combining on-site meeting and teleconference.
3. The board of supervisors should have 3 people, and the actual number of people attending the meeting is 3.
4. The board of supervisors is presided over by Mr. Zhang Yangnan, chairman of the board of supervisors.
5. The convening, convening and voting procedures of this meeting comply with the company law of the people’s Republic of China and other laws and regulations and the relevant provisions of Betta Pharmaceuticals Co.Ltd(300558) articles of association.
2、 Deliberation at the meeting of the board of supervisors
The meeting deliberated and approved the proposal on investment in Wuhan Heyuan Biotechnology Co., Ltd. and related party transactions, in order to expand the new drug innovation technology platform of Betta Pharmaceuticals Co.Ltd(300558) (hereinafter referred to as “the company”) and accelerate the strategic layout of the company in the field of disease treatment, The company plans to subscribe 20010395 ordinary shares of pre IPO series newly issued by Wuhan Heyuan Biotechnology Co., Ltd. with its own capital of 385 million yuan at the price of 19.24 yuan per share. After the completion of this investment, the company is expected to hold 7.60% of its equity (the final shareholding ratio is subject to the register of shareholders after financing). For details, please refer to the company’s disclosure on cninfo.com on the same day（ http://www.cn.info.com.cn. ）Announcement on investment in Wuhan Heyuan Biotechnology Co., Ltd. and related party transactions (Announcement No.: 2022019).
Voting results: 3 in favor, 0 against and 0 abstention. The proposal was passed.
3、 Documents for future reference 1. Resolutions of the 23rd Meeting of Betta Pharmaceuticals Co.Ltd(300558) the third board of supervisors. It is hereby announced.
Betta Pharmaceuticals Co.Ltd(300558) board of supervisors March 4, 2022
